In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 11, 2011, Pages 2066-2076

  Yang, Yunan ^a,b   Zhang, Yin ^c   Hong, Hao ^a   Liu, Glenn ^d   Leigh, Bryan R ^e   Cai, Weibo ^a,c,d  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

^e TRACON Pharmaceuticals Inc   (United States)

Author keywords

Breast cancer; CD105 endoglin; Monoclonal antibody (mAb); Near infrared fluorescence (NIRF) imaging; TRC105; Tumor angiogenesis

Indexed keywords

ANTIBODY CONJUGATE; CD105 MONOCLONAL ANTIBODY; CETUXIMAB; ENDOGLIN; FLUORESCENT DYE CONJUGATED CD105 MONOCLONAL ANTIBODY; FLUORESCENT DYE CONJUGATED CETUXIMAB; IMMUNOGLOBULIN G1 ANTIBODY; MONOCLONAL ANTIBODY; TRC 105; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY LABELING; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG HALF LIFE; DRUG TUMOR LEVEL; EX VIVO STUDY; FEMALE; FLUORESCENCE IMAGING; FLUORESCENCE MICROSCOPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; NEAR INFRARED FLUORESCENCE IMAGING; NONHUMAN; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; BENZENESULFONATES; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; INFRARED RAYS; MICE; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, CELL SURFACE; SPECTROMETRY, FLUORESCENCE;

EID: 80255135569     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1886-x     Document Type: Article

References (40)

1. J Folkman 1995 Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 27 31 7584949 10.1038/nm0195-27 1:CAS:528:DyaK2MXjs1KnsLk%3D
2. E Fonsatti L Del Vecchio M Altomonte L Sigalotti MR Nicotra S Coral, et al. 2001 Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies J Cell Physiol 188 1 7 11382917 10.1002/jcp.1095 1:CAS:528:DC%2BD3MXktVaisLo%3D (Pubitemid 32476491)
3. JM Wang S Kumar D Pye AJ van Agthoven J Krupinski RD Hunter 1993 A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues Int J Cancer 54 363 370 8509210 10.1002/ijc.2910540303 1:STN:280:DyaK3s3osFygug%3D%3D (Pubitemid 23169671)
4. NP Barbara JL Wrana M Letarte 1999 Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily J Biol Chem 274 584 594 9872992 10.1074/jbc.274.2.584 1:CAS:528:DyaK1MXmtFGgsQ%3D%3D (Pubitemid 29058021)
5. A Gougos M Letarte 1990 Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells J Biol Chem 265 8361 8364 1692830 1:CAS:528:DyaK3MXitVWru7Y%3D
6. P Wikström IF Lissbrant P Stattin L Egevad A Bergh 2002 Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer Prostate 51 268 275 11987155 10.1002/pros.10083 (Pubitemid 34556377)
7. FJ Burrows EJ Derbyshire PL Tazzari P Amlot AF Gazdar SW King, et al. 1995 Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy Clin Cancer Res 1 1623 1634 9815965 1:CAS:528:DyaK28XmvVWgsg%3D%3D (Pubitemid 26030991)
8. E Fonsatti AP Jekunen KJ Kairemo S Coral M Snellman MR Nicotra, et al. 2000 Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model Clin Cancer Res 6 2037 2043 10815930 1:CAS:528:DC%2BD3cXktVWitr0%3D (Pubitemid 30305103)
9. NA Dallas S Samuel L Xia F Fan MJ Gray SJ Lim, et al. 2008 Endoglin (CD105): a marker of tumor vasculature and potential target for therapy Clin Cancer Res 14 1931 1937 18381930 10.1158/1078-0432.CCR-07-4478 1:CAS:528:DC%2BD1cXkt1aktbs%3D (Pubitemid 351551101)
10. S Kumar A Ghellal C Li G Byrne N Haboubi JM Wang, et al. 1999 Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis Cancer Res 59 856 861 10029075 1:CAS:528:DyaK1MXht1Sis7s%3D (Pubitemid 29086739)
11. E Fonsatti HJ Nicolay M Altomonte A Covre M Maio 2010 Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours Cardiovasc Res 86 12 19 19812043 1:CAS:528:DC%2BC3cXjt1Gitbs%3D
12. BK Seon A Haba F Matsuno N Takahashi M Tsujie X She, et al. 2011 Endoglin-targeted cancer therapy Curr Drug Deliv 8 135 143 21034418 10.2174/156720111793663570 1:CAS:528:DC%2BC3MXkslSnsbY%3D
13. W Cai J Rao SS Gambhir X Chen 2006 How molecular imaging is speeding up antiangiogenic drug development Mol Cancer Ther 5 2624 2633 17121909 10.1158/1535-7163.MCT-06-0395 1:CAS:528:DC%2BD28Xht1els7jE (Pubitemid 44848989)
14. Y Zhang Y Yang H Hong W Cai 2011 Multimodality molecular imaging of CD105 (endoglin) expression Int J Clin Exp Med 4 32 42 21394284
15. D Zhang XY Feng TD Henning L Wen WY Lu H Pan, et al. 2009 MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105 Eur J Radiol 70 180 189 18541399 10.1016/j.ejrad.2008.04.022
16. G Korpanty PA Grayburn RV Shohet RA Brekken 2005 Targeting vascular endothelium with avidin microbubbles Ultrasound Med Biol 31 1279 1283 16176794 10.1016/j.ultrasmedbio.2005.06.001 (Pubitemid 41318861)
17. G Korpanty JG Carbon PA Grayburn JB Fleming RA Brekken 2007 Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature Clin Cancer Res 13 323 330 17200371 10.1158/1078-0432.CCR-06-1313 1:CAS:528:DC%2BD2sXotlag (Pubitemid 46121886)
18. N Deshpande Y Ren K Foygel J Rosenberg JK Willmann 2011 Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging Radiology 258 804 811 21339349 10.1148/radiol.10101079
19. S Bredow M Lewin B Hofmann E Marecos R Weissleder 2000 Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin Eur J Cancer 36 675 681 10738134 10.1016/S0959-8049(99)00335-4 1:CAS:528:DC%2BD3cXitVSnsLw%3D (Pubitemid 30156855)
20. B Costello C Li S Duff D Butterworth A Khan M Perkins, et al. 2004 Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target Int J Cancer 109 436 441 14961584 10.1002/ijc.11699 1:CAS:528:DC%2BD2cXhvVOgtb4%3D (Pubitemid 38252774)
21. H Hong Y Yang Y Zhang JW Engle TE Barnhart RJ Nickles, et al. 2011 Positron emission tomography imaging of CD105 expression during tumor angiogenesis Eur J Nucl Med Mol Imaging 38 1335 1343 21373764 10.1007/s00259-011-1765-5 1:CAS:528:DC%2BC3MXmvVais7g%3D
22. SY Lee YD Hong PM Felipe MS Pyun SJ Choi 2009 Radiolabeling of monoclonal anti-CD105 with (177)Lu for potential use in radioimmunotherapy Appl Radiat Isot 67 1366 1369 19324561 10.1016/j.apradiso.2009.02.071 1:CAS:528: DC%2BD1MXmvVOlsLc%3D
23. TF Massoud SS Gambhir 2003 Molecular imaging in living subjects: seeing fundamental biological processes in a new light Genes Dev 17 545 580 12629038 10.1101/gad.1047403 1:CAS:528:DC%2BD3sXisVejurY%3D (Pubitemid 36307540)
24. W Cai AR Hsu ZB Li X Chen 2007 Are quantum dots ready for in vivo imaging in human subjects? Nanoscale Res Lett 2 265 281 21394238 10.1007/s11671-007- 9061-9 1:CAS:528:DC%2BD2sXpslegsb0%3D (Pubitemid 47139333)
25. M Tsujie T Tsujie H Toi S Uneda K Shiozaki H Tsai, et al. 2008 Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice Int J Cancer 122 2266 2273 18224682 10.1002/ijc.23314 1:CAS:528: DC%2BD1cXkslynsbs%3D (Pubitemid 351542330)
26. X She F Matsuno N Harada H Tsai BK Seon 2004 Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells Int J Cancer 108 251 257 14639611 10.1002/ijc.11551 1:CAS:528:DC%2BD3sXhtVWgu73P (Pubitemid 37541779)
27. M Tsujie S Uneda H Tsai BK Seon 2006 Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites Int J Oncol 29 1087 1094 17016638 1:CAS:528:DC%2BD28Xht1Wjs7rI
28. DS Mendelson MS Gordon LS Rosen H Hurwitz MK Wong BJ Adams, et al. 2010 Phase I study of TRC105 (anti-CD105 [endoglin] antibody) therapy in patients with advanced refractory cancer J Clin Oncol 28 15s
29. B Vincenzi A Zoccoli F Pantano O Venditti S Galluzzo 2010 Cetuximab: from bench to bedside Curr Cancer Drug Targets 10 80 95 20088790 10.2174/156800910790980241 1:CAS:528:DC%2BC3cXkvFKgur4%3D
30. H Wang W Cai K Chen ZB Li A Kashefi L He, et al. 2007 A new PET tracer specific for vascular endothelial growth factor receptor 2 Eur J Nucl Med Mol Imaging 34 2001 2010 17694307 10.1007/s00259-007-0524-0 1:CAS:528: DC%2BD2sXhtlyiurrP (Pubitemid 350212131)
31. N Takahashi A Haba F Matsuno BK Seon 2001 Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide Cancer Res 61 7846 7854 11691802 1:CAS:528:DC%2BD3MXotlaku70%3D (Pubitemid 33049374)
32. W Cai K Chen KA Mohamedali Q Cao SS Gambhir MG Rosenblum, et al. 2006 PET of vascular endothelial growth factor receptor expression J Nucl Med 47 2048 2056 17138749 1:CAS:528:DC%2BD2sXksFKmsA%3D%3D (Pubitemid 47544993)
33. Y Wu W Cai X Chen 2006 Near-infrared fluorescence imaging of tumor integrin αvβ3 expression with Cy7-labeled RGD multimers Mol Imaging Biol 8 226 236 16791749 10.1007/s11307-006-0041-8 (Pubitemid 44193419)
34. P Carmeliet 2005 Angiogenesis in life, disease and medicine Nature 438 932 936 16355210 10.1038/nature04478 1:CAS:528:DC%2BD2MXhtlSksrjF (Pubitemid 43093958)
35. W Cai X Chen 2007 Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression Front Biosci 12 4267 4279 17485373 10.2741/2386 1:CAS:528:DC%2BD2sXms1KlsLg%3D
36. W Cai X Chen 2008 Multimodality molecular imaging of tumor angiogenesis J Nucl Med 49 Suppl 2 113S 128S 18523069 10.2967/jnumed.107.045922 1:CAS:528:DC%2BD1cXotFahu74%3D (Pubitemid 351948040)
37. W Cai G Niu X Chen 2008 Imaging of integrins as biomarkers for tumor angiogenesis Curr Pharm Des 14 2943 2973 18991712 10.2174/138161208786404308 1:CAS:528:DC%2BD1MXmt1ehsQ%3D%3D
38. SE Duff C Li JM Garland S Kumar 2003 CD105 is important for angiogenesis: evidence and potential applications FASEB J 17 984 992 12773481 10.1096/fj.02-0634rev 1:CAS:528:DC%2BD3sXktl2htLY%3D (Pubitemid 36676386)
39. E Fonsatti L Sigalotti P Arslan M Altomonte M Maio 2003 Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies Curr Cancer Drug Targets 3 427 432 14683500 10.2174/ 1568009033481741 1:CAS:528:DC%2BD3sXhtVSmurjO (Pubitemid 38017479)
40. F Matsuno Y Haruta M Kondo H Tsai M Barcos BK Seon 1999 Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies Clin Cancer Res 5 371 382 10037187 1:CAS:528:DyaK1MXhsVWrtL4%3D (Pubitemid 29085191)